Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) have earned an average recommendation of “Moderate Buy” from the eight research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $52.3333.

Several research firms have issued reports on KNSA. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, October 8th. Wells Fargo & Company upped their target price on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the company an “overweight” rating in a research report on Thursday, September 25th. Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 2nd. Wedbush raised their price objective on shares of Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Finally, TD Cowen assumed coverage on Kiniksa Pharmaceuticals International in a research report on Monday, September 29th. They issued a “buy” rating and a $60.00 price target on the stock.

Insiders Place Their Bets

In other news, Director Barry D. Quart sold 20,129 shares of the business’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $41.51, for a total value of $835,554.79. Following the sale, the director directly owned 12,546 shares in the company, valued at $520,784.46. The trade was a 61.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider John F. Paolini sold 82,542 shares of the stock in a transaction dated Friday, October 31st. The stock was sold at an average price of $37.14, for a total value of $3,065,609.88. Following the transaction, the insider owned 61,324 shares of the company’s stock, valued at approximately $2,277,573.36. The trade was a 57.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 510,689 shares of company stock worth $20,009,290 in the last three months. 53.48% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KNSA. USA Financial Formulas acquired a new position in Kiniksa Pharmaceuticals International during the third quarter valued at approximately $32,000. EverSource Wealth Advisors LLC increased its holdings in shares of Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after acquiring an additional 532 shares during the last quarter. Quarry LP bought a new stake in Kiniksa Pharmaceuticals International in the 3rd quarter valued at $44,000. Osaic Holdings Inc. acquired a new stake in Kiniksa Pharmaceuticals International during the 2nd quarter valued at $31,000. Finally, Farther Finance Advisors LLC boosted its position in Kiniksa Pharmaceuticals International by 582.4% during the third quarter. Farther Finance Advisors LLC now owns 1,358 shares of the company’s stock worth $53,000 after purchasing an additional 1,159 shares during the period. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Stock Up 3.9%

Shares of KNSA stock opened at $39.41 on Friday. Kiniksa Pharmaceuticals International has a 12 month low of $18.12 and a 12 month high of $44.42. The company has a market cap of $2.99 billion, a PE ratio of 87.58 and a beta of 0.04. The business’s 50 day moving average is $41.35 and its two-hundred day moving average is $36.75.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, October 28th. The company reported $0.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The company had revenue of $180.86 million during the quarter, compared to analyst estimates of $166.64 million. During the same quarter in the prior year, the business earned ($0.18) earnings per share. The business’s revenue for the quarter was up 61.2% on a year-over-year basis. As a group, equities analysts expect that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current fiscal year.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.